In short
A new clinical trial is underway to assess the effectiveness and safety of KBP-336, a potential treatment for individuals living with obesity and knee osteoarthritis. This study aims to determine if KBP-336 can reduce knee pain and promote weight loss in this population. The trial will compare KBP-336 to a placebo over a 6-month period, focusing on pain reduction, weight loss, and overall quality of life improvements.
At a glance
- Study Drug
- KBP-336 (Dual Amylin and Calcitonin Receptor agonist)
- Administration
- Weekly subcutaneous injection
- Target Population
- Obese individuals with knee osteoarthritis
- Study Duration
- 6 months (183 days)
- Primary Outcomes
- Change in body weight, Change in WOMAC pain scale
- Secondary Outcomes
- Changes in WOMAC stiffness and function, Quality of life (AQoL 8D), Body composition, Bone mineral density
- Study Design
- Double-blind, Randomized, Placebo-controlled trial
What is KBP-336?
KBP-336 is a new investigational drug being studied for the treatment of knee osteoarthritis in obese individuals. It is currently undergoing a Phase IIa clinical trial to evaluate its effectiveness and safety. KBP-336 is administered as a solution for injection, given subcutaneously (under the skin).
Target Condition: Knee Osteoarthritis in Obese Individuals
The study focuses on individuals who have both knee osteoarthritis and obesity. Osteoarthritis is a condition where the protective cartilage in joints breaks down, causing pain and stiffness. Obesity can worsen osteoarthritis by putting extra stress on the knee joints.
How KBP-336 Works
While the exact mechanism of KBP-336 is not fully described in the provided information, it is classified as a protein-based medication. The study aims to investigate how KBP-336, when used alongside diet and exercise, might help with weight loss and reduce pain associated with knee osteoarthritis.
Clinical Trial Details
The ongoing clinical trial for KBP-336 is described as a double-blind, placebo-controlled, randomized study. This means that: Some participants will receive KBP-336, while others will receive a placebo (a substance with no active ingredients) Neither the participants nor the researchers know who is receiving the actual drug or the placebo Participants are randomly assigned to either the KBP-336 group or the placebo group This design helps ensure that the results of the study are as unbiased as possible.
Potential Benefits of KBP-336
The study aims to evaluate several potential benefits of KBP-336, including: Reduction in body weight Decrease in knee pain related to osteoarthritis Improvement in other osteoarthritis symptoms, such as stiffness and function Enhancement of overall quality of life Changes in body composition, including fat, lean, and bone mass These outcomes will be measured and compared between the KBP-336 and placebo groups to determine the drug's effectiveness.
Eligibility Criteria
To participate in the KBP-336 clinical trial, individuals must meet specific criteria, including: Age 45 or older Body Mass Index (BMI) of 30 kg/m² or higher Diagnosed with knee osteoarthritis for at least 3 months Willing to follow the study requirements, including diet and exercise recommendations Not having had certain treatments, such as knee surgery or specific injections, within a certain timeframe There are also several exclusion criteria, such as certain medical conditions or treatments that would prevent participation.
Safety Considerations
As with any clinical trial, the safety of participants is a top priority. The study will carefully monitor participants for any side effects or adverse reactions to KBP-336. Participants will be required to discontinue certain pain medications during the trial, except for a limited amount of paracetamol as a rescue medication.
It's important to note that KBP-336 is still an investigational drug, and its full safety profile is not yet known. The clinical trial aims to gather more information about both its effectiveness and potential risks.